Early initiation of sodium-glucose linked transporter inhibitors (SGLT-2i) and associated metabolic and electrolyte outcomes in diabetic kidney transplant recipients.
Acute Kidney Injury
/ etiology
Adult
Aged
Diabetic Nephropathies
/ metabolism
Electrolytes
/ metabolism
Female
Follow-Up Studies
Humans
Hypercalciuria
/ etiology
Kidney Transplantation
/ adverse effects
Male
Middle Aged
Nephrocalcinosis
/ etiology
Postoperative Complications
/ etiology
Renal Tubular Transport, Inborn Errors
/ etiology
Retrospective Studies
Risk
Sodium-Glucose Transporter 2 Inhibitors
/ administration & dosage
Time Factors
Treatment Outcome
Weight Gain
Journal
Endocrinology, diabetes & metabolism
ISSN: 2398-9238
Titre abrégé: Endocrinol Diabetes Metab
Pays: England
ID NLM: 101732442
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
11
07
2020
revised:
12
08
2020
accepted:
15
08
2020
entrez:
15
4
2021
pubmed:
16
4
2021
medline:
21
10
2021
Statut:
epublish
Résumé
There is a paucity of data on the use of SGLT2 inhibitors on outcomes in kidney transplant recipients. There may be concern in initiating these agents, especially within the first year post-transplant when renal function is more labile and immunosuppression more intense, due to a presumed high risk of urinary infections and acute kidney injury. This is a retrospective study on 50 kidney transplant recipients, half of whom were started on therapy within the first year of transplant. Over a follow-up period of 6 months, overall patients had a statistically significant improvement in weight by -2.95 kg [SD 3.54,
Identifiants
pubmed: 33855198
doi: 10.1002/edm2.185
pmc: PMC8029504
doi:
Substances chimiques
Electrolytes
0
Sodium-Glucose Transporter 2 Inhibitors
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e00185Informations de copyright
© 2020 The Authors. Endocrinology, Diabetes & Metabolism published by John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
Dr Gaurav Gupta has served on the Scientific Advisory Board of Relypsa. The rest of the authors have no conflicts of interest or financial ties to disclose.
Références
N Engl J Med. 2016 Jul 28;375(4):323-34
pubmed: 27299675
Transplantation. 2010 Mar 15;89(5):612-9
pubmed: 20110856
Am J Transplant. 2019 Mar;19(3):907-919
pubmed: 30585690
Diabet Med. 2006 Oct;23(10):1050-6
pubmed: 16978367
Diabetes Care. 2019 Jun;42(6):1067-1074
pubmed: 30862658
Kidney Med. 2020 Apr 18;2(3):359-364
pubmed: 32734255
Ann Intern Med. 2019 Aug 20;171(4):248-256
pubmed: 31357213
Nephrol Dial Transplant. 2011 Jul;26(7):2362-9
pubmed: 21212164
Diabetologia. 2016 Dec;59(12):2546-2551
pubmed: 27628105
Transpl Int. 2014 Sep;27(9):895-902
pubmed: 24909487